[183]
As such, Apotex submits that the '080 patent fails to teach the invention to which it purportedly relates. In addition, Apotex alleges that the inventors had not demonstrated the actual utility of levofloxacin as a special or substantially advantageous antimicrobial pharmaceutical agent relative to ofloxacin as of June 20, 1985, the date of the first priority application.